文献速递头颈外科

中性粒细胞与淋巴细胞比值与帕博利珠单抗在口腔鳞状细胞癌中的疗效

Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma.
PubMed 文献 · Otolaryngol Head Neck Surg · 2024-12-15

本研究为回顾性观察性研究,纳入2016年5月至2022年5月在加州大学旧金山分校开始帕博利珠单抗治疗的52例复发或转移性口腔鳞状细胞癌患者,评估治疗前中性粒细胞与淋巴细胞比值(NLR)与6个月无进展生存期(PFS)及2年总生存期(OS)的关系。结果显示,6个月PFS为46%,2年OS为44%;治疗前NLR较高与较差的6个月PFS和2年OS独立相关。

要点

  • 治疗前NLR中位数为5.7(四分位距3.6-7.6),6个月PFS为46%,2年OS为44%。
  • NLR与6个月PFS独立相关(HR 1.05,95%CI 1.01-1.11,P=0.028)。
  • NLR与2年OS独立相关(HR 1.12,95%CI 1.05-1.20,P<0.001)。

核心结论

  • 在接受帕博利珠单抗治疗的口腔鳞状细胞癌患者中,较高的治疗前NLR与较差的6个月PFS和2年OS相关。

研究设计与样本

  • 本研究为在三级学术医疗中心进行的回顾性观察性研究,纳入2016年5月至2022年5月在加州大学旧金山分校开始帕博利珠单抗治疗的口腔鳞状细胞癌患者52例。

主要发现

  • 所有患者的免疫检查点抑制剂(ICI)适应症均为复发或转移。
  • 治疗前NLR中位数为5.7(四分位距3.6-7.6)。
  • 27例(55%)患者接受帕博利珠单抗单药治疗。
  • 在ICI前接受复发或转移治疗的患者中,9例(18%)接受挽救性手术加辅助治疗,2例(4%)接受单纯化疗,1例(2%)接受放化疗,10例(20%)接受挽救性手术。
  • 19例(36.5%)患者在开始ICI时存在远处转移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the relationship between pretreatment neutrophil-to-lymphocyte ratio (NLR) and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) oral cavity cancer on pembrolizumab. STUDY DESIGN: This study was a retrospective, observational study performed at a tertiary care academic center. SETTING: Participants included patients with oral cavity squamous cell carcinoma (OCSCC) who began pembrolizumab treatment at the University of California, San Francisco between May 2016 and May 2022. METHODS: The primary outcome was a 6-month PFS. The secondary outcome was a 2-year OS. NLR was treated as a continuous variable. Disease progression was determined using radiographic criteria, adopted from the Response Evaluation Criteria in Solid Tumors. RESULTS: Fifty-two patients with OCSCC were included. Immune checkpoint inhibitor (ICI) indication was recurrence/metastasis for all patients. The median pretreatment NLR was 5.7 (interquartile range: 3.6-7.6). Twenty-seven (55%) patients received pembrolizumab alone. Of those receiving treatment for R/M prior to ICI, 9 (18%) received salvage surgery and adjuvant therapy, 2 (4%) received chemotherapy alone, 1 (2%) received chemoradiation, and 10 (20%) received salvage surgery. Nineteen (36.5%) patients had distant metastases at the start of ICI. Six-month PFS was 46%. Two-year OS was 44%. NLR was independently associated with 6-month PFS [hazard ratio, HR: 1.05 (95% confidence interval, CI: 1.01-1.11), P = .028] and 2-year OS [HR: 1.12 (95% CI: 1.05-1.20), P < .001]. CONCLUSION: Higher pretreatment NLR was associated with poorer 6-month PFS and 2-year OS in OCSCC patients treated with pembrolizumab.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Truong AA, Lee RH, Wu X, et al. Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2024. PMID: 39675043. doi:10.1002/ohn.1088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。